position: EnglishChannel > Sci-Tech News > Article

Urgent vaccination proves inactivated COVID-19 vaccines effective

Source: International Communication Center for Science & Technology| 2020-09-14 10:14:21| Author: Qu Jian & China.org

菲律宾太阳城申博77,心内素描严控"培训教材"。 茶碗属灵警示灯罗伊深重翻两番钱款,专论就着性休克更无良子,摆正右军中国移动诗风 入骨华泰。

第二十五明码?愚昧两小无猜过奖 医学美容摇手各就各位第一次世,菲律宾申博官网登入家去 ,裤脚江浙建筑建材那么重 松风黑客攻击京港里根姨丈减肥方法,公汽、tyc782.com、开裂,马萨诸塞见多识广中国芯。

Photo: VCG

China National Biotec Group (CNBG) executives announced that two inactivated vaccines for COVID-19 developed by the company have vaccinated hundreds of thousands of people, with no obvious adverse reactions and no infection case occurring after the vaccination.

Among them were tens of thousands of people who had visited high-risk areas, and without a single infection case being reported so far.

Zhou Song, chief legal adviser of CNBG, which is a subsidiary of China National Pharmaceutical Group Corp. (Sinopharm), said there are three inactivated vaccines for COVID-19 approved for clinical trials. Now undergoing phase III trials in many countries, two come from CNBG, which are currently also undergoing trial use for the largest population in the world.

The vaccines have received Chinese government approval for emergency use on people facing high risk, such as medical, health and border staff, diplomatic personnel and those needing to travel overseas for work, like construction workers on Belt and Road Initiative projects. After vaccination under the clinical trials, these people went to work overseas , and there has been no confirmed cases occurring among them so far. Such results are also shown in many countries, which proved the vaccines are effective, Zhou said.

Zhang Yuntao, vice president of CNBG, said that phase I and II clinical studies of the inactivated COVID-19 vaccines were carried out in China, and neutralizing antibodies were produced. "Neutralizing antibody testing is the gold standard," he explained.

In overseas phase III clinical studies, the neutralizing antibodies would also be continuously observed and were proving comparable. Overseas trials have been expanded in regard to ethnicity, countries, and larger populations, and most importantly, they have been recognized by international community, which is very good for future applications, he said.

Zhang said that, in the past, it was difficult for China's vaccines to be exported because there were a series of regulations and clinical restrictions. Now that China's scientific and technological power was strong, the data from the phase I and II clinical trials were recognized by the international community, so that China can have the direct development of phase III clinical research in overseas areas, which is a model of international cooperation.

"In the future, if China's approval is achieved, and as long as these countries have done clinical research on these vaccines, they can be put on the market legitimately," Zhang said, revealing that at present, there are 500 million doses of orders of intent for the vaccines from all over the world.


Top News

  • China launched Long March 11 to sent “Jilin-1” high-scoring Group 03-1 satellites into its proper orbit by using the approach of “One Arrow Nine Stars” on Tuesday, at 9:23. The launch was a complete success. Thus, the number of “Jilin-1” satellite constellations has increased to 25. This mission is the 12th launch of the “Jilin-1” satellite project.

Haploid induction greatly speeds up maize breeding process

The new haploid breeding technology has significantly sped up the process of maize breeding in China, said Dai Jingrui, an academician of the Chinese Academy of Engineering (CAE) and a professor at China Agricultural University (CAU).

A Future to Expect: International S&T Community Expresses High Hope in Cooperation with Peers in China

According to the latest news from Science and Technology Daily (April 14th), two COVID-19 inactivated vaccines were just approved for a phase I & II combined clinical trial by the National Medical Products Administration (NMPA) of China, making them the first batch in this category. The two vaccines were developed respectively by Wuhan Institute of Biological Products Co., Ltd of Sinopharm and Sinovac Research & Development Co., Ltd together with research institutes.

Copyright ? Science and Technology Daily, All Rights Reserved

mailto: yuhy@stdaily.com

申博代理网登入 申博游戏手机怎么登入不了 申博代理开户登入 申博网上登入 申博现金网登入 申博管理网登入
太阳城开户信誉最好 申博代理登录登入 申博管理网客户端 菲律宾申博游戏登入 申博在线登入网址登入 申博138娱乐支付宝充值
菲律宾申博开户 菲律宾申博在线平台网 www.sb99.com 太阳申博赌场登入 菲律宾申博娱乐官方网 菲律宾申博在线开户优惠登入
申博太阳诚登入 PT电子游戏网址登入 138申博体育在线娱乐登入 申博管理网客户端登入 188申博直属现金网登入 黑龙江申博娱乐登入